Prescription medication · LAMA / LABA Combination
tiotropium/olodaterol
Also sold as Stiolto Respimat. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).
Data updated 2026-05-15
- 3
- InteractionsFew interactions
- Rx
- Availability
tiotropium/olodaterol (Stiolto Respimat) is a prescription LAMA / LABA Combination. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).
Stiolto Respimat combines two medicines to help you breathe better if you have COPD. It is used long-term to manage your COPD symptoms.
Verify with FDA → · CMS NADAC pricing →
What it does
Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD).
Common side effects
Common cold symptoms (nasopharyngitis), Cough, Back pain
Key warnings
Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma.
The sections below are summarized in plain English from tiotropium/olodaterol's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Stiolto Respimat contains two medicines that open your airways. Tiotropium helps to relax the muscles around your airways. Olodaterol is a long-acting beta-agonist (LABA) that also relaxes airway muscles.
How to Take It
Use Stiolto Respimat exactly as your doctor tells you. Inhale two puffs from the inhaler once a day. Use it at the same time each day. Do not use more than two puffs in 24 hours.
This is a plain-language summary of tiotropium/olodaterol's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant. Stiolto Respimat should be used during pregnancy only if the benefit outweighs the risk to the baby. It is not known if Stiolto Respimat passes into breast milk.
This is a plain-language summary of tiotropium/olodaterol's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time.
This is a plain-language summary of tiotropium/olodaterol's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Store Stiolto Respimat at room temperature, away from freezing temperatures.
Serious Warnings
Using LABA medicines like Stiolto Respimat without a steroid medicine can be dangerous if you have asthma. Stiolto Respimat is not meant to treat asthma. Do not use Stiolto Respimat for sudden breathing problems. Using too much Stiolto Respimat can cause serious heart problems and may be fatal. If you have a bad reaction, like swelling or rash, stop using Stiolto Respimat and get medical help.
Known Drug Interactions
Avoid administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs. ( 7.6 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT, may be potentiated [see Warnings and Precautions (5.3 , 5.6 , 5.10 , 5.11) ] . Although the clinical significance of these effects is not known, caution is advised in the co-administration of STIOLTO RESPIMAT with non-potassium sparing diuretics.
Mechanism: Using two inhalers that contain the same medicine can cause you to have too much of the drug in your system. This can lead to a fast heartbeat, shakiness, or other heart-related problems.
What to do: Avoid using these two medications at the same time. Your doctor should check your prescriptions to make sure you are not using duplicate treatments.
Avoid administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs. ( 7.6 ) 7.1 Adrenergic Drugs If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT, may be potentiated [see Warnings and Precautions (5.3 , 5.6 , 5.10 , 5.11) ] . Although the clinical significance of these effects is not known, caution is advised in the co-administration of STIOLTO RESPIMAT with non-potassium sparing diuretics.
Mechanism: Both of these medicines contain the same type of drug, and taking them together can cause an overdose of those effects.
What to do: Do not use these two medications at the same time.
7.7 Inhibitors of Cytochrome P450 and P-gp Efflux Transporter In a drug interaction study using the strong dual CYP and P-gp inhibitor ketoconazole, a 1.7-fold increase of olodaterol maximum plasma concentrations and AUC was observed [see Pharmacokinetics (12.3) ] .
Mechanism: Ketoconazole stops the body from breaking down the olodaterol part of this medicine properly. This leads to a buildup of the drug in your system, which could increase the risk of side effects.
What to do: Use this combination with caution and tell your doctor if you notice any new or worsening symptoms.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
Can I use Stiolto Respimat for asthma?
What should I do if Stiolto Respimat doesn't seem to be working?
Can I use a spacer with Stiolto Respimat?
How do I know when my Stiolto Respimat inhaler is empty?
Can I use Stiolto Respimat for sudden breathing problems?
What if I get Stiolto Respimat in my eyes?
Can I use Stiolto Respimat with other inhalers?
How long does Stiolto Respimat take to work?
Is Stiolto Respimat a steroid?
How often should I clean my Stiolto Respimat inhaler?
What are the common side effects of tiotropium/olodaterol?
Does tiotropium/olodaterol interact with other medications?
What drug class is tiotropium/olodaterol?
Is tiotropium/olodaterol safe during pregnancy?
Related Medications in LAMA / LABA Combination
Other drugs grouped near tiotropium/olodaterol - same-class peers and common alternatives.
aclidinium
Tudorza Pressair
Compare with tiotropium/olodaterol →
albuterol
Ventolin, ProAir
Albuterol is a drug that helps you breathe easier.
Compare with tiotropium/olodaterol →
albuterol/ipratropium
Combivent Respimat, DuoNeb
Combivent Respimat is a combination medicine that helps open your airways.
Compare with tiotropium/olodaterol →
beclomethasone
Qvar
Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.
Compare with tiotropium/olodaterol →
benralizumab
Fasenra
Fasenra is a medicine that can help treat severe asthma and EGPA.
Compare with tiotropium/olodaterol →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on tiotropium/olodaterol
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for tiotropium/olodaterol
The FDA label for tiotropium/olodaterol (sold under brand names such as Stiolto Respimat) classifies it as a prescription-only medication in the LAMA / LABA Combination class. Stiolto Respimat is used to treat chronic obstructive pulmonary disease (COPD). Official labeling lists 3 commonly reported side effects, including Common cold symptoms (nasopharyngitis), Cough, Back pain.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 3 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: June 30, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages